Welcome to Awesome Blog Design perfect blog
Business, Healthcare

Bristol Myers Squibb showcases research advancing outcomes addressing hard-to-treat blood cancers and diseases across small molecule, biologic and cell therapies at ASH 2020

Results for our CD19-targeted CAR T cell therapy lisocabtagene maraleucel (liso-cel) in patients with heavily pretreated mantle cell lymphoma and relapsed/refractory chronic lymphocytic leukemia Data showcasing BCMA-targeted CAR T cell therapy idecabtagene vicleucel (ide-cel), including updated results from the Phase 1 CRB-401

Business, Healthcare

KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) demonstrated statistically significant improvement in Progression-Free Survival (PFS), Overall Survival (OS) and Objective Response Rate (ORR) versus Sunitinib as first-line treatment for patients…

LENVIMA Plus Everolimus Also Showed Statistically Significant Improvement in PFS and ORR Endpoints Versus Sunitinib Results of Investigational Phase 3 KEYNOTE-581/CLEAR Trial (Study 307) to be Presented at Upcoming Medical Meeting KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK): KEYTRUDA®